Biodesix Lifts 2026 Outlook After Strong Q1 Beat

Overview

• Biodesix reported Q1 revenue of $25.6 million, up 42% year over year, and lifted its 2026 outlook to $108–$114 million after early-quarter weather and FedEx disruptions.
• Diagnostic testing revenue rose 37% as test volumes grew 29% with higher average prices, and primary care clinics accounted for 15% of total test volume.
• Development services revenue jumped 99% from a year ago, and the CFO said some revenue was recognized early in Q1 and should normalize over the rest of the year.
• Gross margin improved to 84% on scale, pricing, and workflow gains, the net loss narrowed to $7.8 million, and cash ended at $25.6 million including $16.8 million from market proceeds.
• The company plans to add sales reps and continue funding research to expand access to its lung diagnostics and advance its pipeline.